28 results about "Endopeptidase" patented technology

The invention relates to application of an asparagine endopeptidase inhibitor in preparation of a medicine for improving insulin resistance. According to the application, starting from inhibiting the aging driving factor AEP, the AEP inhibitor is tried to be applied to the research of insulin resistance for the first time, and the AEP inhibitor is found to be capable of remarkably improving glucose tolerance and insulin sensitivity. Therefore, the invention provides the application of the asparagine endopeptidase inhibitor in preparation of the medicine for improving insulin resistance. Experiments prove that the AEP inhibitor not only can significantly enhance insulin sensitivity of old mice and improve glucose tolerance, but also can reduce serum low-density lipoprotein cholesterol and lactic dehydrogenase levels, shows multiple improvement effects on glucose metabolism and lipid metabolism, and also can be used for preparing the AEP inhibitor. After long-term administration, obvious toxic and side effects are not found in pathological examinations of blood routine examination, urine routine examination, heart, liver, spleen, lung, kidney and other important organs, so that the traditional Chinese medicine composition is proved to have good safety and is suitable for long-term intervention of chronic diseases.

The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA / DNA) or variants thereof.

This invention provides a physiological age prediction model that predicts the physiological age of a subject by detecting urinary proteins and metabolites in a urine sample. The aforementioned urinary proteins and metabolites are those that change significantly with age, including one or more selected from the following: cartilage intermediate layer protein (CILP2), collagen Alpha 1 chain (COFA1), myristic acid, 12-methyltridecanoic acid, CN family member 5 (CCN5), Sushi domain-containing protein 5 (SUSD5), procollagen C endopeptidase enhancer 1 (PCOLCE), and L-lactate oxidase (LOX), preferably including all of the aforementioned urinary proteins and metabolites.

Compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5, and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

The invention relates to a T cell intracellular antigen TIA1 truncation body protein tTIA1 and application thereof, and the T cell intracellular antigen TIA1 truncation body protein tTIA1 is tTIA1-N with an amino acid sequence as shown in SEQ ID NO.1 and / or tTIA1-C with an amino acid sequence as shown in SEQ ID NO.2. The T cell intracellular antigen TIA1 truncation body protein tTIA1 is a TIA1-N protein with an amino acid sequence as shown in SEQ ID NO.1. The tTIA1-N and the tTIA1-C are generated by carrying out targeted enzyme digestion on an intracellular antigen TIA1 of a T cell by virtue of asparagine endopeptidase AEP, so that the tTIA1-N and the tTIA1-C have relatively high sensitivity and accuracy and a very strong application prospect.

The invention provides an application of recombinant DL-endopeptidase and a metabolite thereof in preparation of a medicine for preventing late-onset septicemia of a premature infant, and solves the technical problems of poor prevention effect, obvious side effect, limited clinical applicability and the like of the late-onset septicemia of the premature infant in the field of neonatal intensive care medicine for a long time. A brand-new and reliable technical support is provided for prevention and control of late-onset septicemia of premature infants, and technical innovation and development in the field of neonatal infectious disease prevention are promoted.

An anhydrous composition comprising an endolysin derived from a Staphylococcus aureus phage and mannitol. The present invention relates to an anhydrous composition comprising (i) at least one endolysin derived from a Staphylococcus aureus phage; and (ii) mannitol, the endolysin comprising a protein sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of the reference amino acid sequences SEQ ID NO: 1 and SEQ ID NO: 2. It also relates to a composition comprising, in a physiologically acceptable medium, at least one anhydrous composition of the invention.It also covers the use of such a composition to prevent and / or treat a skin disorder related to Staphylococcus aureus colonization in an individual in need, and a non-therapeutic cosmetic process for the care of keratinous materials comprising at least one step of topical application of such a composition to said keratinous materials. Finally, it covers a process for stabilizing an endolysin derived from a Staphylococcus aureus phage. Figure for the abstract: None.

This invention discloses the use of Pv-PEP1 protein in the treatment of gluten-contaminated feed. The use of Pv-PEP1 protein or related biological materials in at least one of the following: A1) treating gluten-contaminated feed; A2) preparing a product for treating gluten-contaminated feed; wherein the amino acid sequence of said Pv-PEP1 protein comprises the sequence shown in SEQ ID No:4. The Pv-PEP1 protein of this invention exhibits a significantly superior degradation effect on gluten in contaminated feed compared to currently reported Aspergillus niger prolyl endopeptidase (AN-PEP) and similar commercially available products, demonstrating significant technical advantages and broad application prospects.

Compounds having the structure of formula (I) and their pharmaceutically acceptable salts are disclosed, wherein X 1 R 1 R 2 R 3 R 4 R 5 and R 6 This refers to: pharmaceutical compositions comprising such compounds and salts as defined in the specification; the use of such compounds and salts for the treatment or prevention of prolyl endopeptidase fibroblast activation protein (FAP)-mediated diseases; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts. Formula (I):

The invention relates to the technical field of biology, in particular to a method for treating insulin analogues through sequential enzyme digestion so as to improve the enzyme digestion yield. The method comprises the step of carrying out specific enzyme digestion on the proinsulin analogue by using recombinant double-base amino acid endopeptidase (Kex-2 enzyme) and recombinant trypsin in sequence, and comprises the following steps: firstly, adding the Kex-2 enzyme to perform enzyme digestion on double bases between Linker-A chains to generate an intermediate peptide 1, and then adding the recombinant trypsin to cut a guide peptide and a connecting peptide to obtain a target product. According to the method, the enzyme digestion yield can be remarkably increased by 25% or above, meanwhile, miscut impurities generated by single recombinant trypsin enzyme digestion are avoided, and the method is suitable for efficient enzyme digestion in insulin analogue production.

The invention provides an application of a combined composition of antibiotics and bacteria carrying DL-endopeptidase in preparation of a medicine for preventing intestinal development delay of premature infants, the combined composition comprises a component A and a component B which are prepared according to a specific mass ratio, the component A is selected from broad-spectrum antibiotics in an intensive care unit of newborns, and the component B is selected from bacteria carrying DL-endopeptidase and bacteria carrying DL-endopeptidase and bacteria carrying DL-endopeptidase and bacteria carrying DL-endopeptidase. And the component B is a strain which can secrete DL-endopeptidase and has endogenous drug resistance to the component A. According to the application, synergism of'clearing 'and'driving' is realized, the traditional clinical thinking of'first sterilization and then remediation 'is broken, pathogenic microorganisms (such as klebsiella and staphylococcus aureus) in a premature infant body are cleared through antibiotics, and meanwhile, bacterial components in the components are synchronously utilized to down-regulate protein expression of the intestinal mucosa intracellular cylindricity disease, so that the premature infant is prevented from suffering from the intestinal mucosa intracellular cylindricity disease, and the premature infant is prevented from suffering from the intestinal mucosa intracellular cylindricity disease. The synthesis of tight junction protein is actively realized.

L'Oréal Cosmetic Composition Comprising an Endolysin Derived from a Staphylococcus aureus Phage and 4-Hydroxyacetophenone. The present invention relates to a composition, particularly a cosmetic one, comprising, in a physiologically acceptable medium, at least one endolysin derived from a Staphylococcus aureus phage and 4-hydroxyacetophenone. It also relates to the use of such a composition to prevent and / or treat a skin disorder related to colonization by Staphylococcus aureus in an individual in need, and in particular to prevent and / or treat acne and / or eczema in an individual in need, and a non-therapeutic cosmetic method for the care of keratinous materials, particularly skin, comprising at least one step of topical application of such a composition to said keratinous materials. Figure for abstract: None

The invention provides a method for preparing horse F (ab ') 2 and horse Fab' preparations by a multi-enzyme one-pot method, which is characterized by comprising the following steps of: preparing a polyclonal horse IgG (immunoglobulin G) solution by taking high immune horse plasma or serum as a raw material, putting the polyclonal horse IgG solution into a reactor, and adding recombinant IgG specific endopeptidase IdeZ2 and recombinant IgG specific endopeptidase IdeS to obtain a primary reaction solution; controlling the reaction pH and the reaction temperature of the polyclonal horse IgG solution in the reactor to obtain an intermediate reaction solution; changing the reaction pH and reaction temperature of the intermediate reaction solution in the reactor, and adding a reducing agent to obtain a termination reaction solution; and carrying out Protein A, Protein G or Protein A / G affinity chromatography on the termination reaction solution to remove residual complete IgG and Fc fragments, and then carrying out metal chelating chromatography to remove IdeZ2 free enzyme and IdeS free enzyme so as to finally obtain the horse F (ab ') 2 and Fab' preparations. According to the whole process, the completeness of key neutralizing subclasses is maintained, Fc is fully removed, controllable conversion of antibody fragments is achieved, and the problems that in a traditional process, structural damage is large, and stability is poor are effectively solved.

The present invention is directed to a method for manufacturing an enzyme preparation, comprising at least one recombinant Actinoallomurus endopeptidase with glutenase activity, at high yields and suitable for human use. The invention is further directed to a recombinant expression vector for expressing the recombinant endopeptidase(s) of interest, and to a S. lividans host cell comprising said vector. Moreover, the present invention is directed the enzyme preparation obtained by said method, to formulations of the same and to clinical uses thereof.

Cosmetic composition comprising an endolysin derived from a Staphylococcus aureus phage and an oil. The present invention relates to a composition, particularly a cosmetic one, comprising, in a physiologically acceptable medium, at least one endolysin derived from a Staphylococcus aureus phage and at least one oil distinct from a paraffin oil. It also relates to the use of such a composition to prevent and / or treat a skin disorder related to colonization by Staphylococcus aureus in an individual in need, in particular to prevent and / or treat acne and / or eczema in the individual, and a non-therapeutic cosmetic method for the care of keratinous materials, particularly of the skin, comprising at least one step of topical application of such a composition to said keratinous materials. Figure for abstract: None

Disclosed is a pharmaceutical composition for preventing or treating a brain disease, containing as an active ingredient an ErbB3-binding protein 1 (EBP1) protein or a polynucleotide sequence encoding the EBP1 protein, wherein an EBP1 N84A / N204A protein, which is an EBP1 mutant in an asparagine endopeptidase (AEP)-uncleavable form, and a polynucleotide encoding the same can reduce amyloid beta production and enhance cognitive function in the early stages of Alzheimer's disease, and thus the composition can be advantageously used as a therapeutic agent for brain diseases including sporadic Alzheimer's disease.

The application provides a preparation method of a seasoning base and a river snail soup base, and relates to the technical field of food seasonings. The application adopts a combination of alkaline protease, flavor protease and proline endopeptidase as an enzymolysis agent to perform enzymolysis on river snail meat, so as to obtain a seasoning base with low bitterness value, high freshness score and high comprehensive score, which is suitable for preparing a river snail soup base. Further, the three enzymes can be used for step-by-step enzymolysis, so as to further improve the enzymolysis effect.

The present application relates to the technical field of food processing, and discloses a softening enzymolysis process of bird's nest small molecule peptide material based on gradient temperature control, which comprises the following steps: firstly, gradient temperature rising physical softening is performed on bird's nest slurry to gently relax the compact structure thereof; then, three-stage sequential enzymolysis is performed in sequence, that is, preliminary degradation is performed by endoprotease, further cutting is performed by exoprotease, and finally, depth and directional enzymolysis is performed by glycoside hydrolase and specific endopeptidase in cooperation; and the product is obtained after inactivation, separation, refinement and drying. Through the gradient temperature control physical softening, three-stage sequential enzymolysis and integration of the front and rear processes, the present application solves the problems existing in the prior art, such as poor substrate accessibility, low enzymolysis efficiency and specificity, wide product distribution, non-outstanding functional ingredients and loose process flow.

The present invention discloses the use of a Pv-PEP1 protein in the treatment of a gluten contaminated material. The use of a Pv-PEP1 protein, or a biological material related thereto, in at least one of: A1) treating a gluten contaminated material; a2) preparing a product for treating the gluten contaminated material; the amino acid sequence of the Pv-PEP1 protein comprises a sequence as shown in SEQ ID No: 4. The degradation effect of the Pv-PEP1 protein on gluten in polluted materials is far better than that of aspergillus niger prolyl endopeptidase (AN-PEP) and similar commercially available products reported at present, and the Pv-PEP1 protein shows remarkable technical advantages and wide application prospects.

The application provides a preparation method of yak bone collagen peptide, a composition for promoting bone development and application thereof, and relates to the technical field of health foods.The preparation method comprises the following steps: after ultrasonic pretreatment of yak bone, supercritical CO2 is used for defatting to obtain a defatted product; the defatted product is mixed with a deodorizing agent to obtain a deodorized product; the deodorizing agent is an aqueous solution of a plant extract; the plant extract is at least one selected from the group consisting of Amomum tsao-ko extract, turmeric extract, green tea extract and momordica grosvenori extract; the deodorized product is subjected to enzymolysis reaction through a fixed immobilized enzyme reactor, the complex enzyme is prolyl endopeptidase, papain and ficin; a crude product is obtained; the crude product is subjected to ultrafiltration through a filter membrane with a molecular weight cut-off of 1kDa and is subjected to macroporous resin adsorption.The yak bone collagen peptide and the composition prepared by the method can significantly improve body length, promote bone development and promote the secretion of growth hormone, and meet the growth needs of children.

Provided herein is the use of endopeptidase and protein deamidase with specificity to cleave after Arg and / or Lys for obtaining dairy alternative food products with improved foaming properties.

The present invention is directed to new systems for the production of recombinant proteins in Streptomyces host strain. The new system includes vectors and new recombinant host strains, in particular for the production of Actinoallomurus endopeptidases.

This invention discloses a biotechnology-based process and product for preparing deodorized mushroom concentrate, relating to the field of mushroom concentrate technology. The invention involves taking finely filtered mushroom broth, concentrating it, and controlling the solid content to obtain a mushroom concentrate. The mushroom concentrate is then adjusted to pH using sodium hydroxide or hydrochloric acid, heated, and immobilized bromelain and papain are added, stirred, and then immobilized flavor protease is added, stirred, and filtered to obtain the deodorized mushroom concentrate. Bromelain, papain, and flavor protease are selected. Bromelain and papain are endopeptidases that cleave long protein chains in mushrooms at different sites, providing more ends for the flavor protease. The flavor protease is an exopeptidase that hydrolyzes the protein fragments cleaved by bromelain and papain to form flavor amino acids. During the enzymatic hydrolysis process, the immobilized carriers of the three enzymes remove off-odors through adsorption.

Disclosed herein are methods for harvesting an antibody as a recombinant protein comprising an asparaginyl endopeptidase (AEP, legumain) cleavage site containing the amino acids NF, by maintaining the pH after fermentation at 4.6 to 5.3 for acidification to precipitate impurities in order to prevent the self-cleavage of proenzyme and thus the activation of peptidase at lower pH, as well as methods for inhibiting the cleavage of a recombinant protein comprising an AEP cleavage site during a bioproduction process.

The invention belongs to the technical field of food protein processing, and particularly relates to a method for preparing a low-sensitization and low-bitterness whey protein hydrolysate through a limited enzymolysis process regulated by endopeptidase and exopeptidase, which comprises the following steps of: properly hydrolyzing and separating whey protein through trypsin, chymotrypsin, alkaline protease and flavourzyme; the method is used for obtaining optimal enzymolysis conditions of low allergenicity, low bitterness and high processing characteristics of whey protein. The enzymolysis product with the hydrolysis degree of 5% shows excellent emulsibility and foamability and lower bitterness, when the hydrolysis degree of the alkaline protein enzymolysis product is 5%, the antigenicity is reduced by 70.51%, the bitterness of the flavor protein enzymolysis product is the lowest, and the emulsibility of the enzymolysis product with the hydrolysis degree of trypsin being 5% is improved by 6.45%.